Chinese biopharma is gaining ground, producing oncology drugs that rival established Western pharmaceuticals like those associated with Merck.
1 report, 0 independent
Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Chinese biopharma is gaining ground, producing oncology drugs that rival established Western pharmaceuticals like those associated with Merck.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- LG Chem and OTR Therapeutics announce a strategic collaboration to leverage China's life science ecosystem for oncology R&D.Sub-event
- Institutional investors bought and sold stock in Summit Therapeutics.Sub-event
- An NDA was granted for an oncology drug for use in the Chinese market.Sub-event
- Summit Therapeutics presented data on a cancer drug targeting the immune system at the ASCO conference in Chicago.Sub-event
- Chinese biopharma is emerging as a serious competitor to major Western drug companies like Merck and Novartis.
Keep exploring
The entities involved
-
Summit Therapeutics
biopharmaceutical company
Nothing else this week.
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Merck
public company in Indonesia
Related events
- Partnership expands Novartis's oncology pipeline.
- Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
- Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.
- An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.
Coverage
Newest first; wire copies grouped- Unknown outlet